| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Institut National de la Santé et de la Recherche Médicale, 403 Research Unit (P.S., P.D.D.), Hôpital Edouard Herriot, 69437 Lyon, France; Hôpital Neuro-Cardiologique (B.C.), 69003 Lyon, France; and Société de Secours Minière de Bourgogne (F.M.), 71300 Montceau les Mines, France
Address all correspondence and requests for reprints to: Prof. Pierre D. Delmas, Institut National de la Santé et de la Recherche Médicale (INSERM), Research Unit 403, Hôpital Edouard Herriot, place d’Arsonval, 69437 Lyon, France. E-mail: delmas{at}lyon.inserm.fr.
The goal of this study was to identify the clinical and biological patterns of hypogonadism in a cohort of 1040 elderly men. Residual androgenic activity was estimated by total testosterone as well as the apparent free testosterone concentration (AFTC) and free testosterone index (FTI) calculated on the basis of concentrations of SHBG and total testosterone using appropriate formulae. The lower limit of the normal range defined by 2 SD below the mean in 150 healthy, nonobese, and nonsmoking men, aged 19–40 yr, was calculated for total testosterone (9.26 nmol/liter), AFTC (146 pmol/liter), and FTI (0.14 nmol/nmol). The prevalence of hypogonadism increased with ageing. Hypogonadal men were older and heavier (due to a higher fat body mass) and had lower concentrations of 17ß-estradiol and androstenedione than men with normal androgenic activity. Men with decreased AFTC had a slightly lower bone mineral density (BMD) at certain sites. Men with decreased FTI had lower appendicular skeletal muscle mass and relative skeletal muscle index. For all three measures of androgenic activity, hypogonadal men had increased levels of the markers of bone resorption. In the multiple regression models including both 17ß-estradiol and testosterone (total, AFTC, or FTI), 17ß-estradiol was the only significant determinant of BMD. In the multiple regression models including 17ß-estradiol and AFTC or FTI, only testosterone was a significant determinant of the variability in bone formation markers, whereas both 17ß-estradiol and testosterone were significant determinants of the variability of the markers of bone resorption. Hypogonadism was associated with an increase in the risk of falls, an impairment of static and dynamic balance, as well as the inability to stand up from a chair and to perform the tandem walk. Decreased AFTC (<146 pmol/liter) discriminated best men with functional disabilities (odds ratio, 1.54–7.95; P < 0.05–0.0001). Hypogonadal elderly men had increased bone resorption that was not adequately matched by an increase in bone formation, lower muscle strength, impaired static and dynamic balance, a higher risk of falls, and, in men with low AFTC, a slightly lower BMD. Low AFTC seems to have the best discriminative power for densitometric, biochemical, and functional parameters, followed by FTI, whereas total testosterone was the least discriminative. In multiple regression models, 17ß-estradiol was the strongest determinant of BMD, and AFTC and FTI were significant determinants of the variability in bone formation markers, whereas both 17ß-estradiol and testosterone determined the variability in bone resorption markers.
This work was supported by a contract from INSERM/Merck Sharp & Dohme (Chibret, France).
This work was presented in abstract form (oral presentation) at the 24th Annual Meeting of the American Society for Bone and Mineral Research, San Antonio, TX [J Bone Miner Res, 2002, 17(Suppl 1):S174, Abstract 1209].
Abbreviations: AFTC, Apparent free testosterone concentration; BAP, bone-specific alkaline phosphatase; BMD, bone mineral density; ßCTX-1, ß-isomerized C-terminal telopeptide of collagen type I; DPD, deoxypyridinoline; FTI, free testosterone index; 25OHD, 25-hydrocholecalciferol; PADAM, partial androgen deficiency in ageing men; PINP, propeptide of type I collagen; SSMB, Société de Secours Minière de Bourgogne.
This article has been cited by other articles:
 |
|
 |
|
  E. S. LeBlanc, C. M. Nielson, L. M. Marshall, J. A. Lapidus, E. Barrett-Connor, K. E. Ensrud, A. R. Hoffman, G. Laughlin, C. Ohlsson, E. S. Orwoll, et al. The Effects of Serum Testosterone, Estradiol, and Sex Hormone Binding Globulin Levels on Fracture Risk in Older Men J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3337 - 3346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Szulc Pathophysiology and Diagnosis of Osteoporosis in Aging Men IBMS BoneKEy, October 1, 2008; 5(10): 370 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lehtonen, R. Huupponen, J. Tuomilehto, S. Lavonius, S. Arve, H. Isoaho, I. Huhtaniemi, and R. Tilvis Serum testosterone but not leptin predicts mortality in elderly men Age Ageing, July 1, 2008; 37(4): 461 - 464. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wald, M. Miner, and A. D. Seftel State of the Art Reviews: Male Menopause: Fact or Fiction? American Journal of Lifestyle Medicine, April 1, 2008; 2(2): 132 - 141. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Orwoll, L. C. Lambert, L. M. Marshall, J. Blank, E. Barrett-Connor, J. Cauley, K. Ensrud, S. R. Cummings, and for the Osteoporotic Fractures in Men Study Group Endogenous testosterone levels, physical performance, and fall risk in older men. Arch Intern Med, October 23, 2006; 166(19): 2124 - 2131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Kaufman and A. Vermeulen The Decline of Androgen Levels in Elderly Men and Its Clinical and Therapeutic Implications Endocr. Rev., October 1, 2005; 26(6): 833 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Y. Takahashi, P. Y. Liu, P. D. Roebuck, A. Iranmanesh, and J. D. Veldhuis Graded Inhibition of Pulsatile Luteinizing Hormone Secretion by a Selective Gonadotropin-Releasing Hormone (GnRH)-Receptor Antagonist in Healthy Men: Evidence That Age Attenuates Hypothalamic GnRH Outflow J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2768 - 2774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Page, J. K. Amory, F. D. Bowman, B. D. Anawalt, A. M. Matsumoto, W. J. Bremner, and J. L. Tenover Exogenous Testosterone (T) Alone or with Finasteride Increases Physical Performance, Grip Strength, and Lean Body Mass in Older Men with Low Serum T J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1502 - 1510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Nieschlag, H.M. Behre, P. Bouchard, J.J. Corrales, T.H. Jones, G.K. Stalla, S.M. Webb, and F.C.W. Wu Testosterone replacement therapy: current trends and future directions Hum. Reprod. Update, September 1, 2004; 10(5): 409 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Szulc, F. Duboeuf, F. Marchand, and P. D Delmas Hormonal and lifestyle determinants of appendicular skeletal muscle mass in men: the MINOS study Am. J. Clinical Nutrition, August 1, 2004; 80(2): 496 - 503. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
